title: Discovery of BRM Targeted Therapies: Novel Reactivation of an Anti-cancer Gene.
abstract: Drug discovery in the field of oncology has been advanced mainly through the targeting of receptor tyrosine kinases. Both antibodies and small molecule inhibitors have been found to have successful applications in blocking the proliferative functions of these cell surface receptors. Based on these early successes, additional kinases within the cytoplasm have been found to promote cancer and, as such, have been recognized as feasible targets for additional modes of therapies. Unlike these oncogene targets, most tumor suppressors are irreversibly altered during cancer progression and therefore are not feasible targets for therapy. However, a subset of these genes is reversibly epigenetically suppressed. One such gene is BRM, and when it is re-expressed in cancer cells, this gene halts their growth. Moreover, as the key catalytic subunit of the SWI/SNF complex, BRM is centrally important to a host of anticancer pathways and cellular mechanisms, and its status may serve as a biomarker. Restoring its expression will both reconnect a number of growth-controlling pathways and affect cellular adhesion, DNA repair, and immune functions. For these reasons, restoring BRM expression is not only feasible, but potentially a potent form of anticancer therapy. To identify BRM-restoring compounds, we developed a cell-based luciferase assay. In this review, we discuss some of the challenges we encountered, issues related to this type of drug discovery, and our future ambitions. We hope this review will provide insight to this type of endeavor and lead to more investigations pursuing this type of drug research.
authors.affiliation: Department of Medicine, Division of Hematology/Oncology, University of Florida, Gainesville Florida 32611, USA.
authors.forename: Sarah
authors.initials: S
authors.lastname: Gramling
authors.forename: David
authors.initials: D
authors.lastname: Reisman
keywords: Anticancer; Brahma; Epigenetic suppression; High throughput screening; SWI/SNF; Tumor suppressor
references.citation: J Mol Diagn. 2003 May;5(2):73-81
references.pmid: 12707371
references.citation: Cold Spring Harb Symp Quant Biol. 2005;70:241-50
references.pmid: 16869760
references.citation: Oncogene. 2009 Jul 9;28(27):2492-501
references.pmid: 19448667
references.citation: J Med Chem. 2002 Feb 14;45(4):818-40
references.pmid: 11831894
references.citation: Mol Cells. 2005 Apr 30;19(2):289-93
references.pmid: 15879716
references.citation: Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3364-9
references.pmid: 10725359
references.citation: Oncogene. 2002 Feb 14;21(8):1196-207
references.pmid: 11850839
references.citation: EMBO Rep. 2009 Jul;10(7):776-82
references.pmid: 19498465
references.citation: J Biomol Screen. 1999;4(2):67-73
references.pmid: 10838414
references.citation: J Biol Chem. 2001 Mar 23;276(12):9273-8
references.pmid: 11108719
references.citation: Cell. 2000 Mar 31;101(1):79-89
references.pmid: 10778858
references.citation: J Biol Chem. 2008 May 2;283(18):11924-34
references.pmid: 18303029
references.citation: EMBO J. 2003 Dec 15;22(24):6505-15
references.pmid: 14657023
references.citation: J Cancer Res Clin Oncol. 1996;122(6):319-27
references.pmid: 8642041
references.citation: Biochem Cell Biol. 2001;79(3):243-52
references.pmid: 11467738
references.citation: Oncogene. 2005 Aug 18;24(35):5471-81
references.pmid: 16007216
references.citation: Cell. 1994 Oct 7;79(1):119-30
references.pmid: 7923370
references.citation: J Biol Chem. 2006 Nov 17;281(46):35305-15
references.pmid: 16990270
references.citation: Oncogene. 2011 Jul 21;30(29):3295-304
references.pmid: 21478907
references.citation: Mol Cell Biol. 2007 Feb;27(4):1280-95
references.pmid: 17158926
references.citation: Nat Struct Mol Biol. 2006 Jan;13(1):22-9
references.pmid: 16341228
references.citation: Oncogene. 2007 Oct 25;26(49):7058-66
references.pmid: 17546055
references.citation: Oncogene. 2009 Apr 9;28(14):1653-68
references.pmid: 19234488
references.citation: EMBO J. 2006 Sep 6;25(17):3986-97
references.pmid: 16932743
references.citation: EMBO J. 1998 Dec 1;17(23):6979-91
references.pmid: 9843504
references.citation: Cell Cycle. 2008 Apr 15;7(8):1067-74
references.pmid: 18414052
references.citation: Mol Cell Biol. 1996 Apr;16(4):1576-83
references.pmid: 8657132
references.citation: J Biol Chem. 2002 Nov 1;277(44):41674-85
references.pmid: 12200431
references.citation: Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7748-53
references.pmid: 10884406
references.citation: J Biol Chem. 2002 Jun 21;277(25):22330-7
references.pmid: 11950834
references.citation: Mol Cell Biol. 2003 Sep;23(17):6210-20
references.pmid: 12917342
references.citation: Mol Cell Biol. 1996 Jan;16(1):437-41
references.pmid: 8524326
references.citation: DNA Repair (Amst). 2009 Jan 1;8(1):29-39
references.pmid: 18822392
references.citation: Nature. 1998 May 7;393(6680):88-91
references.pmid: 9590696